Core Viewpoint - The article discusses the evolving strategies of multinational companies in China, highlighting their deep integration into local markets and communities, as well as the shift from mere manufacturing to a comprehensive value chain presence [3][5]. Group 1: Investment Trends - In 2025, the number of newly established foreign-invested enterprises in China increased by 19.1%, while the actual use of foreign capital decreased by 9.5%, indicating a complex investment landscape [3]. - German companies' investment in China reached over 7 billion euros in the first eleven months of 2025, marking a 55.5% increase compared to the same period in 2024 and 2023 [3][8]. - The Chinese manufacturing sector's negative list for foreign investment has been fully cleared, enhancing the market's attractiveness to foreign capital, particularly in advanced manufacturing and modern service industries [9]. Group 2: Corporate Strategies - Companies like Epson are adapting to local needs by developing tailored solutions, such as AI learning assistants and customized industrial robots, to address specific market demands [7][8]. - Hitachi Elevator has established its largest factory and R&D team in China, focusing on modernization and energy-efficient technologies in response to the urban renewal wave [8]. - Karcher has upgraded its Shanghai headquarters and expanded production capacity, achieving a 30% growth in early 2025, emphasizing the importance of understanding local market dynamics [11]. Group 3: Innovation and Market Adaptation - Companies are increasingly focusing on creating value through innovation, transitioning from raw material dependency to high-value specialty chemicals, as seen with Lanxess's investment in Qingdao [12]. - The trend indicates that the Chinese market is becoming a key driver of global technological innovation and business model evolution, necessitating deeper commitments from companies to integrate with local ecosystems [12].

Group 1 - The A-share market saw a collective decline on May 16, while the Sci-Tech Innovation Pharmaceutical sector rebounded, with the Sci-Tech Innovation Pharmaceutical ETF (588860) rising by 0.16% [1] - Notable stocks in the sector included Maiwei Biotech-U, which increased by over 5%, along with Shouyao Holdings-U, KQ Biotech, Innotec, CanSino, and Baotai, all of which experienced gains [1] - The Sci-Tech Innovation Pharmaceutical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which selects 50 large-cap companies in biopharmaceuticals and related fields to reflect the overall performance of representative companies in the sector [1] Group 2 - According to CMB International, the optimization of centralized procurement policies in mainland China provides hospitals and enterprises with more flexibility and autonomy, benefiting leading prescription drug companies [2] - The anticipated implementation of favorable policies, such as the 2025H2 medical insurance category, is expected to accelerate industry consolidation, with the sector's valuations remaining at historical lows [2] - The recommendation is to focus on innovative drug targets with high growth potential or clear breakeven timelines after short-term sentiment stabilizes [2]